title: GM-CSF/Ipilimumab combination extends melanoma survival.
abstract: In a phase II trial, combining the granulocyte-macrophage colony-stimulating factor sargramostin and the CTLA-4 inhibitor ipilimumab prolonged survival and caused fewer serious side effects in patients with metastatic melanoma compared with ipilimumab alone.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D015201:Meta-Analysis as Topic; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D011994:Recombinant Proteins; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor